[The Barclays iShares and Genentech Acquisitions] Deals Are Done – Now Comes the Fun

Business and organizational observers in San Francisco and its environs will get a first hand view of how smart – or not-so-smart – the buyers of Genentech and Barclays Global Investor’s iShares unit are in getting real value for their acquisitions. [Update: See Kathleen Pender’s good overview column Net Worth from the April 12th  San Francisco Chronicle here ]

While the buyers are different, the name of the game is the same: get value equal or greater to your purchase price.Read the rest

[Through the Glass Door] Barclays Global Investors and Genentech: Stuck in the M & A Middle?

In Roman Catholic theology, limbo is that afterlife condition for those who die without being assigned to hell. For employees in companies waiting for the post-acquisition dust to settle such as Genentech, or for those waiting for part of the organization to be halved off, such as Barclays Global Investors (BGI) with its iShares division,  limbo is a pretty good description of what it’s like to be inside the organization.Read the rest

10 Secrets Headhunters (Usually) Don’t Tell You – Part 7 of the series “Choose Me, Hire Me!”

Headlines blare: “Why You Should Hire Me.” While times may be challenged, there is work (and jobs) to be had. I’ve been in the people (and teams) coaching business for over 25 years , both as a coach to managers and teams and also as someone directly responsible for hiring thousands of people through roles running large staffing / recruiting operations.Read the rest